FORM OF WARRANTFirst Wave BioPharma, Inc. • March 14th, 2024 • Pharmaceutical preparations • Delaware
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Lender Support LetterCredit Agreement • March 14th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations
AGREEMENT AND PLAN OF MERGER among: FIRST WAVE BIOPHARMA, INC.; IMMUNO MERGER SUB I, INC.; IMMUNO MERGER SUB II, LLC; and IMMUNOGENX, INC. Dated as of March 13, 2024Agreement and Plan of Merger • March 14th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations • Delaware
FORM OF PATENT AND TRADEMARK SECURITY AGREEMENTPatent and Trademark Security Agreement • March 14th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations • Colorado
This Patent and Trademark Security Agreement (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of _____, 2024, is made by and between IMMUNOGENX, INC., a Delaware corporation, having a business address of 1600 Dove Street, Suite 330, Newport Beach, CA 92660 (together with its affiliates, successors and assigns, “Borrower”), and _____ (together with its affiliates, successors and assigns, “Lender”).
CREDIT AGREEMENT Dated as of October 3, 2022 IMMUNOGENX, INC. as Borrower and MATTRESS LIQUIDATORS, INC. as LenderCredit Agreement • March 14th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations • Colorado
This Credit Agreement is entered into as of October 3, 2022, by and between IMMUNOGENX, INC., a Delaware corporation (“Borrower”), and MATTRESS LIQUIDATORS, INC., a Colorado corporation (together with its successors and assigns, “Lender”). All capitalized terms used herein without definition shall have the same meanings herein as such terms are defined in Section 1.1 hereof.
SECURITY AGREEMENTSecurity Agreement • March 14th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations • Colorado
THIS SECURITY AGREEMENT (this “Security Agreement”) is entered into as October 3, 2022, by and between IMMUNOGENX, INC., a Delaware corporation (“Borrower”), and MATTRESS LIQUIDATORS, INC., a Colorado corporation, its successors and assigns (“Lender”).
